Cocrystal Pharma COCP 深 沪
等待开盘 09-17 09:30:00 美东时间
1.32
-0.110
-7.69%
华盛通- 最 高1.40
- 今 开1.40
- 成交量 62.28万股
- 最 低 1.29
- 昨 收 1.43
- 总市值 1342.94万
- 52周最高 3.26
- 市盈率 静 --
- 换手率 6.12%
- 52周最低 1.12
- 委 比 32.64%
- 总股本 1017.38万
- 历史最高 66.00
- 量 比 0.04
- 振 幅 7.69%
- 历史最低 1.12
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cocrystal Pharma Raises $4.75M in Direct Offering
Cocrystal Pharma ( ($COCP) ) has provided an update. On September 15, 2025, Coc...
09-16 05:03
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Check-Cap (NASDAQ:CHEK) stock increased by 353.1% to $3.38 during Mond...
09-15 20:10
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Cocrystal Pharma raised $4.7 million via direct offering of 2.76 million shares at $1.70 each, with up to $8.3 million more from warrants exercisable at $1.50 per share. Proceeds will fund working capital and corporate purposes.
09-12 13:43
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
Cocrystal Pharma, Inc. announced that President Sam Lee highlighted CDI-988, a potential first oral antiviral for norovirus prevention and treatment, at the International Calicivirus Conference. CDI-988 showed favorable safety and tolerability in Phase 1 studies, with FDA clearance for a Phase 1b human challenge study. The drug targets a conserved region in viral proteases, leveraging Cocrystal's proprietary structure-based platform technology. N...
09-12 12:00
Cocrystal Pharma Receives Study May Proceed Letter From FDA To Conduct Phase 1b Challenge Study Evaluating CDI-988 For Prevention And Treatment Of Norovirus Infections; Phase 1b Challenge Study Is Planned To Begin Before Year-End 2025
There are currently no approved vaccines or treatments for norovirus infectionCocrystal's CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by norovirus
09-08 20:01
Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment
Cocrystal Pharma received FDA approval for a Phase 1b study of CDI-988, a novel oral antiviral targeting norovirus infections. With no approved vaccines or treatments for norovirus, CDI-988 is the first potential option for its prevention and treatment. The study is set to begin by late 2025. CDI-988 has shown broad-spectrum activity against key norovirus strains and demonstrated a favorable safety profile in Phase 1 trials. Norovirus is a leadin...
09-08 12:00
Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference
Cocrystal Pharma, Inc. announced that its CFO and co-CEO, James Martin, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 12:00 p.m. Eastern time. Mr. Martin will be available for in-person and virtual one-on-one meetings. Investors and professionals can register to attend virtually or in-person at the Lotte New York Palace Hotel. Cocrystal Pharma, a clinical-stage biotechnolo...
09-03 12:00
Cocrystal Pharma Q2 EPS $(0.20) Beats $(0.30) Estimate
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 62.26 percent increase over losses of $(0.53) per share from
08-14 20:13
Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma reports positive safety and tolerability results for CDI-988 in Phase 1 trials, with plans for a human challenge study later this year to evaluate its effectiveness against norovirus. Both CDI-988 and CC-42344 are advancing in clinical trials, targeting norovirus and coronaviruses, influenza A, and other viral threats. The company also provided financial updates, including reduced R&D expenses and a net loss, while cash reserves ...
08-14 12:00
Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
Cocrystal Pharma's CDI-988, an oral pan-viral protease inhibitor, demonstrated favorable safety and tolerability in a Phase 1 study across doses of 100 mg to 1200 mg. The company plans to initiate a Phase 1b study in norovirus-infected subjects later this year. Norovirus currently has no approved treatments or vaccines, creating a critical unmet medical need. CDI-988 targets viral replication and could offer broad-spectrum protection against noro...
08-05 12:00
